Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, February 2012, Pages: 64

Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Narcolepsy Therapeutics market. The report identifies the key trends shaping and driving the global Narcolepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Narcolepsy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Narcolepsy Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Narcolepsy Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Narcolepsy Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Narcolepsy Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Narcolepsy Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Narcolepsy Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Narcolepsy Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Narcolepsy Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Narcolepsy Therapeutics - Introduction
2.1 Disease Overview
2.1.1 Narcolepsy with Cataplexy
2.1.2 Narcolepsy without Cataplexy
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Quality of Life Parameters
2.3 Etiology and Pathophysiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Actigraphy
2.5.2 Multiple Sleep Latency Test (MSLT)
2.5.3 Polysomnography (PSG)
2.5.4 Hypocretin Test
2.6 Treatment and Management Options
2.6.1 Non-Pharmacological Treatment
2.6.2 Pharmacological Treatment
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 NarcolepsyTherapeutics - Market Characterization
3.1 Overview
3.2 Narcolepsy Therapeutics Market Size (2006-2011) - Global
3.3 Narcolepsy Therapeutics Market Forecast (2011-2019) - Global
3.4 Narcolepsy Therapeutics Market Size (2006-2011) - The US
3.5 Narcolepsy Therapeutics Market Forecast (2011-2019) - The US
3.6 Narcolepsy Therapeutics Market Size (2006-2011) - France
3.7 Narcolepsy Therapeutics Market Forecast (2011-2019) - France
3.8 Narcolepsy Therapeutics Market Size (2006-2011) - Germany
3.9 Narcolepsy Therapeutics Market Forecast (2011-2019) - Germany
3.10 Narcolepsy Therapeutics Market Size (2006-2011) - Italy
3.11 Narcolepsy Therapeutics Market Forecast (2011-2019) - Italy
3.12 Narcolepsy Therapeutics Market Size (2006-2011) - Spain
3.13 Narcolepsy Therapeutics Market Forecast (2011-2019) - Spain
3.14 Narcolepsy Therapeutics Market Size (2006-2011) - The UK
3.15 Narcolepsy Therapeutics Market Forecast (2011-2019) - The UK
3.16 Narcolepsy Therapeutics Market Size (2006-2011) - Japan
3.17 Narcolepsy Therapeutics Market Forecast (2011-2019) - Japan
3.18 Drivers and Barriers for the Narcolepsy Therapeutics Market
3.18.1 Drivers for the Narcolepsy Therapeutics Market
3.18.2 Barriers for the Narcolepsy Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 Narcolepsy Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Narcolepsy Therapeutics Market
4.3.1 Provigil (modafinil)
4.3.2 Nuvigil (armodafinil)
4.3.3 Xyrem (sodium oxybate)
4.4 Key Takeaway
5 Narcolepsy Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Narcolepsy Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Narcolepsy Therapeutics - Phase III Pipeline
5.3.2 Narcolepsy Therapeutics - Phase II Pipeline
5.3.3 Narcolepsy Therapeutics - Pre-Clinical Pipeline
5.3.4 Narcolepsy Therapeutics -Discovery Pipeline
5.3.5 Technology Trends Analytic Framework
5.4 Narcolepsy Therapeutics Market - Pipeline by Mechanism of Action
5.5 Molecule Profile for Promising Drugs under Clinical Development
5.5.1 BF2.649 (pitolisant)
5.6 Key Takeaway
6 Narcolepsy Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Narcolepsy Therapeutics Clinical Trials
7 Narcolepsy Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Narcolepsy Therapeutics: Implications for Future Market Competition
8 Narcolepsy Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Bioprojet
8.2.2 Jazz Pharmaceuticals, Inc.
8.2.3 Teva Pharmaceuticals
9 Narcolepsy Therapeutics - Licensing and Partnership Deals
10 Narcolepsy Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Narcolepsy Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 2: Narcolepsy Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 3: Narcolepsy Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 4: Narcolepsy Therapeutics Market, The US, Forecasts ($m), 2011-2019
Table 5: Narcolepsy Therapeutics Market, France, Revenue ($m), 2006-2011
Table 6: Narcolepsy Therapeutics Market, France, Forecasts ($m), 2011-2019
Table 7: Narcolepsy Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 8: Narcolepsy Therapeutics Market, Germany, Forecasts ($m), 2011-2019
Table 9: Narcolepsy Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 10: Narcolepsy Therapeutics Market, Italy, Forecasts ($m), 2011-2019
Table 11: Narcolepsy Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 12: Narcolepsy Therapeutics Market, Spain, Forecasts ($m), 2011-2019
Table 13: Narcolepsy Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 14: Narcolepsy Therapeutics Market, The UK, Forecasts ($m), 2011-2019
Table 15: Narcolepsy Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 16: Narcolepsy Therapeutics Market, Japan, Forecasts ($m), 2011-2019
Table 17: Average Sleep Latencies (In Minutes) on The MWT at Baseline for the Controlled Trials
Table 18: Percentages of Patients Who Showed Degree of Improvement on the CGI-C in the Clinical Trials
Table 19: Average Baseline Sleep Latency and Change from Baseline at Final Visit (MWT and MSLT in minutes)
Table 20: Clinical Global Impression of Change (CGI-C)
Table 21: Summary of Outcomes in Clinical Trials Supporting the Efficacy of Sodium Oxybate
Table 22: Clinical Global Impression of Change in Day and Nighttime Symptoms
Table 23: Narcolepsy Therapeutics - Phase III Pipeline, 2011
Table 24: Narcolepsy Therapeutics - Phase II Pipeline, 2011
Table 25: Narcolepsy Therapeutics - Pre-Clinical Pipeline, 2011
Table 26: Narcolepsy Therapeutics - Discovery Pipeline, 2011
Table 27: Narcolepsy Therapeutics - Clinical Trials by Country, 2011
Table 28: Narcolepsy Therapeutics - Clinical Trials by Phase, 2011
Table 29: Narcolepsy Therapeutics - Clinical Trials by Status
Table 30: Narcolepsy Therapeutics - Prominent Sponsors, 2011
Table 31:Narcolepsy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 32: Bioprojet - Pipeline for Narcolepsy, 2011
Table 33: Narcolepsy Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures
Figure 1: Pharmacological Treatment of Narcolepsy
Figure 2: Referral Pathway for Narcolepsy
Figure 3: Narcolepsy Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 4: Narcolepsy Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 5: Narcolepsy Therapeutics Market, the US, Revenue ($m), 2006-2011
Figure 6: Narcolepsy Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 7: Narcolepsy Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 8: Narcolepsy Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 9: Narcolepsy Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 10: Narcolepsy Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 11: Narcolepsy Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 12: Narcolepsy Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 13: Narcolepsy Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 14: Narcolepsy Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 15: Narcolepsy Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 16: Narcolepsy Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 17: Narcolepsy Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 18: Narcolepsy Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 19: Opportunity and Unmet Need for EDS in the Narcolepsy Therapeutics Market
Figure 20: Opportunity and Unmet Need for Cataplexy in the Narcolepsy Therapeutics Market
Figure 21: Narcolepsy Therapeutics - Strategic Competitor Assessment, 2011
Figure 22: Narcolepsy Therapeutics - Pipeline by Phase of Development, 2011
Figure 23: Narcolepsy Therapeutics - Technology Trends Analytics Framework, 2011
Figure 24: Narcolepsy Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 25: Narcolepsy Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 26: Clinical Trial Details of BF2.649 (pitolisant)
Figure 27: Narcolepsy Therapeutics - Clinical Trials by Country, 2011
Figure 28: Narcolepsy Therapeutics - Clinical Trials by Phase, 2011
Figure 29: Narcolepsy Therapeutics - Clinical Trials by Status, 2011
Figure 30: Narcolepsy Therapeutics - Overall Sponsors, 2011
Figure 31: Narcolepsy Therapeutics - Prominent Sponsors, 2011
Figure 32: Narcolepsy Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 33: Narcolepsy Therapeutics Market, Drivers and Restraints 2011
Figure 34: Implications for Future Market Competition in the Narcolepsy Market, 2011
Figure 35: Narcolepsy Therapeutics Market - Pipeline by Company, 2011
Figure 36: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Narcolepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Narcolepsy Therapeutics market. The report identifies the key trends shaping and driving the global Narcolepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Narcolepsy Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Narcolepsy Therapeutics Market to Show Overall Low Growth until 2019

GlobalData’s analysis indicates that the global narcolepsy therapeutics market was valued at approximately $780m in 2011. The narcolepsy therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 16.9% from 2006-2011, mainly driven by the increased uptake of Provigil (modafinil) in the market and launch of Nuvigil (armodafinil) in the US in 2009 by Cephalon. With a projected CAGR of 0.6%, the market value is expected to increase to $820.9m by 2019. The overall growth of the market is expected to be low, characterized by market share wars, during the forecast period. The primary reason for the restricted growth of the narcolepsy therapeutics market is the entry of generics for Provigil in 2012. The entry of generics will lead to increased price competitiveness in the market, thereby impacting the market valuations. Provigil was the first approved product for treating Excessive Day Time Sleepiness (EDS) in narcolepsy and has the highest share in the narcolepsy therapeutics market. Though its patent expiry is in 2014, the generic entry will be in 2012, which will lead to a decrease in market valuations. However, the impact of the genericization is expected to only restrict the market during 2012-2014.

The expected launch of a Phase III pipeline product by Bioprojet SCR, BF2.649 (pitolisant) (for the treatment of EDS) in 2015 is expected to drive the narcolepsy therapeutics market though the rest of the forecast period (2015-2019). Increasing awareness and intent to treat the condition as well as an increasing patient pool will also contribute to the growth of the market during this period.

Weak Pipeline for Narcolepsy Therapeutics Market

GlobalData’s analysis demonstrates that the narcolepsy therapeutics developmental pipeline is weak, with only six molecules in various phases of development. There is one late stage molecule, BF2.649, which is a first-in-class product and is expected to launch during the forecast period (2011-2019). In Phase II there are three molecules. Of the six molecules in the pipeline, four of them are first-in class, while the exact mechanism of action of two products (C-10291 and flumazenil) is not available. There is no molecule in Phase I, and there is only one molecule in both the pre-clinical and discovery stages.

Bioprojet
Jazz Pharmaceuticals, Inc
Teva Pharmaceuticals

Customers who bought this item also bought

• Narcolepsy Therapeutics - Global Strategic Business Report
• Medical Nutrition - A Global Market Overview
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Disinfectants - Global Strategic Business Report
• Diabetes Diagnostics - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
• Molecular Diagnostics - Global Strategic Business Report
• Cord Blood Stem Cells – A Global Market Overview
• Wheelchairs (Powered and Manual) - Global Strategic Business Report